DK3436593T3 - Fremgangsmåder til varmeinaktivering af adenovirus - Google Patents

Fremgangsmåder til varmeinaktivering af adenovirus Download PDF

Info

Publication number
DK3436593T3
DK3436593T3 DK17776462.8T DK17776462T DK3436593T3 DK 3436593 T3 DK3436593 T3 DK 3436593T3 DK 17776462 T DK17776462 T DK 17776462T DK 3436593 T3 DK3436593 T3 DK 3436593T3
Authority
DK
Denmark
Prior art keywords
adenovirus
methods
heat inactivation
inactivation
heat
Prior art date
Application number
DK17776462.8T
Other languages
English (en)
Inventor
James D Maratt
Christopher J Morrison
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Application granted granted Critical
Publication of DK3436593T3 publication Critical patent/DK3436593T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17776462.8T 2016-03-28 2017-03-28 Fremgangsmåder til varmeinaktivering af adenovirus DK3436593T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314116P 2016-03-28 2016-03-28
PCT/US2017/024545 WO2017172772A1 (en) 2016-03-28 2017-03-28 Methods of heat inactivation of adenovirus

Publications (1)

Publication Number Publication Date
DK3436593T3 true DK3436593T3 (da) 2023-02-20

Family

ID=59966403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17776462.8T DK3436593T3 (da) 2016-03-28 2017-03-28 Fremgangsmåder til varmeinaktivering af adenovirus

Country Status (17)

Country Link
US (3) US11013774B2 (da)
EP (2) EP4159867A1 (da)
JP (3) JP7356224B2 (da)
KR (1) KR102389674B1 (da)
CN (1) CN109196106A (da)
AU (1) AU2017241777B2 (da)
CA (1) CA3018380A1 (da)
DK (1) DK3436593T3 (da)
ES (1) ES2938833T3 (da)
FI (1) FI3436593T3 (da)
HU (1) HUE061100T2 (da)
IL (1) IL261914B2 (da)
LT (1) LT3436593T (da)
PL (1) PL3436593T3 (da)
PT (1) PT3436593T (da)
SG (1) SG11201808183PA (da)
WO (1) WO2017172772A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US12460196B2 (en) 2018-04-27 2025-11-04 Qiagen Gmbh Method for isolating nucleic acids from plant samples
US20210238580A1 (en) * 2018-05-11 2021-08-05 Qiagen Gmbh Lysis method for plant samples
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
DK3898981T5 (da) 2018-12-18 2024-08-05 Ultragenyx Pharmaceutical Inc Fremgangsmåder og sammensætninger til behandling af glykogenlagringssygdomme
JP7560475B2 (ja) 2019-04-12 2024-10-02 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 操作された産生細胞株ならびにそれを作製および使用する方法
JP2023031782A (ja) * 2021-08-25 2023-03-09 株式会社東芝 ウィルス検出方法
JP2025509328A (ja) 2022-03-07 2025-04-11 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 改良されたバッチaav産生システムおよび方法
JP2024020941A (ja) * 2022-08-02 2024-02-15 株式会社東芝 ウイルス不活性化装置およびウイルス不活性化方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えdnaウイルスベクター
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5688676A (en) * 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
ES2099678B1 (es) * 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6541258B2 (en) 1996-12-18 2003-04-01 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
IT1297074B1 (it) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
CA2340682A1 (en) 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
EP1124976A1 (en) 1998-10-27 2001-08-22 Crucell Holland B.V. Improved aav vector production
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
JP2002541792A (ja) * 1999-04-09 2002-12-10 アベンテイス・フアルマ・ソシエテ・アノニム 感染性の組換えアデノウイルスの保存用組成物
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
DE10061533B4 (de) 2000-12-11 2006-05-04 Amphenol-Tuchel Electronics Gmbh Selbsttragende Kontaktfeder, insbesondere für einen Smartcard-Connector
US6492327B2 (en) * 2000-12-19 2002-12-10 Sulzer Biologics Inc. Isolation of purified TGF- β1 and TGF -β2 from bone tissue
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
US7622562B2 (en) * 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
BRPI0511764B8 (pt) * 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
US7195394B2 (en) 2004-07-19 2007-03-27 Vijay Singh Method for resonant wave mixing in closed containers
US8980247B2 (en) 2004-10-21 2015-03-17 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells
AU2006304997B2 (en) 2005-10-20 2012-03-01 Uniqure Ip B.V. Improved AAV vectors produced in insect cells
CN101472941B (zh) * 2006-03-31 2017-08-08 沃弗-威斯康星校友研究基金会 用于疫苗的高滴度重组流感病毒
ES2785223T3 (es) 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV
GB0706638D0 (en) 2007-04-04 2007-05-16 Mbda Uk Ltd A high-dielectric material
US9404150B2 (en) * 2007-08-29 2016-08-02 Sequenom, Inc. Methods and compositions for universal size-specific PCR
US8580755B2 (en) 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
US20110251547A1 (en) 2008-11-07 2011-10-13 Intelligentnano Inc. Transfection with magnetic nanoparticles and ultrasound
KR101812813B1 (ko) * 2009-06-16 2017-12-27 젠자임 코포레이션 재조합 aav 벡터에 대한 개선된 정제 방법
WO2013096955A1 (en) 2011-12-23 2013-06-27 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
BR122020002822B1 (pt) 2013-01-08 2023-04-18 Genzyme Corporation Método para cultivar um vetor de hsv-1 d27.1

Also Published As

Publication number Publication date
KR20180130531A (ko) 2018-12-07
IL261914A (en) 2018-10-31
IL261914B1 (en) 2023-03-01
PT3436593T (pt) 2023-01-31
JP2019509747A (ja) 2019-04-11
JP2021072838A (ja) 2021-05-13
IL261914B2 (en) 2023-07-01
US11944658B2 (en) 2024-04-02
US20240252562A1 (en) 2024-08-01
CA3018380A1 (en) 2017-10-05
KR102389674B1 (ko) 2022-04-21
EP3436593A4 (en) 2019-10-16
AU2017241777A1 (en) 2018-10-11
AU2017241777B2 (en) 2022-02-03
BR112018069703A2 (pt) 2019-02-05
US20190083554A1 (en) 2019-03-21
US11013774B2 (en) 2021-05-25
SG11201808183PA (en) 2018-10-30
US20220072073A1 (en) 2022-03-10
PL3436593T3 (pl) 2023-03-27
FI3436593T3 (fi) 2023-03-16
CN109196106A (zh) 2019-01-11
LT3436593T (lt) 2023-03-10
EP3436593B1 (en) 2022-11-23
JP2022166304A (ja) 2022-11-01
EP3436593A1 (en) 2019-02-06
JP7682837B2 (ja) 2025-05-26
HUE061100T2 (hu) 2023-05-28
ES2938833T3 (es) 2023-04-17
JP7356224B2 (ja) 2023-10-04
WO2017172772A1 (en) 2017-10-05
EP4159867A1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
HUE061100T2 (hu) Adenovírus hõinaktiválásának módszerei
DK3515937T3 (da) Behandling af refraktorisk migræne
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3183505T3 (da) Underlag til positionering af varmeelementer og gulvanlæg
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3261726T3 (da) Sammensætning til behandling af acne
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner